Navigation Links
Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:11/9/2012

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --Event:

HCV Connection Media BriefingDate:

Monday, November 12Time:

7:45 a.m. Eastern Standard TimeWhere:

Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199; Also available by Webcast (link will be provided upon request)The content of the media briefing will include the following themes and information:

  • An overview of HCV and the current epidemic worldwide
  • A compelling historical and scientific context for understanding the new era of HCV therapies and the emergence of patient-guided therapy
  • A brief review of first and second-generation direct-acting antiviral therapies, including important new developments in drug discovery
  • A detailed look at Achillion Pharmaceutical's portfolio aimed at curing HCV in a complex and diverse patient population
  • Following the briefing there will be a Question & Answer session with leading experts in HCV including:

  • Fred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and Alamo Medical Research, San Antonio, Texas
  • Andrew Muir, MD, Director, Gastroenterology and Hepatology Research Group, Duke Clinical Research Institute, Durham, North Carolina
  • The session will also be moderated by Lisa Stark of ABC News
  • Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.


    '/>"/>
    SOURCE Achillion Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
    2. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
    4. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
    5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    6. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
    7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
    8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    9. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
    11. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
    (Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
    (Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
    (Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
    (Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
    Breaking Medicine News(10 mins):